On September 3, 2026, Polyrizon Ltd. entered into a securities purchase agreement to raise approximately $4.0 million through a registered direct offering and concurrent private placement with a single institutional investor. The company sold 232,500 ordinary shares at $12.00 per share in the registered direct offering. In the private placement, it issued 70,833 pre-funded warrants exercisable at $0.00001 and 333,333 ordinary share warrants with a $12.00 exercise price and five-year term. Aegis Capital Corp. served as the sole placement agent for an aggregate fee of 8.0% plus expenses. The transactions are expected to close on or about September 4, 2026, with proceeds designated for general corporate purposes, working capital, and strategic acquisitions. Polyrizon Ltd. is a development-stage biotech company specializing in innovative intranasal hydrogels delivered via nasal sprays.
